Shivalik Rasayan Ltd will close its trading window for directors, designated employees, and other insiders starting October 1, 2026. This restriction applies until two days after the company declares its un-audited financial results for the quarter ending September 2026.

Regulatory compliance and scope

The decision aligns with the company's Code of Conduct for preventing insider trading, in compliance with SEBI (Prohibition of Insider Trading) Regulations. It also adheres to the Code of Practices and Procedures for fair disclosure of Unpublished Price Sensitive Information (UPSI). The closure covers Directors, Designated Employees, and other specified persons classified as Insiders under the regulatory framework.

Board meeting schedule

The exact date for the Board Meeting to approve the Q2FY27 results has not been finalized. The company stated that the date will be intimated to the stock exchanges in due course. Until the results are declared and the subsequent two-day period elapses, trading in the company's securities remains prohibited for the affected group.

Key details of the closure

This procedural step ensures that no insider trading occurs while material price-sensitive information regarding the quarterly performance is being prepared and reviewed by the Board.

Shivalik Rasayan approved a preferential allotment of 2,82,000 equity shares and 9,47,990 fully convertible warrants in its board meeting held on September 14, 2026. The transaction raises ₹30.75 crore from promoter and public category investors.

The Board of Directors authorized the issue at a price of ₹250 per security. The equity share allotment targets public investors, while the warrant issuance includes both promoter group entities and public participants.

Equity Share Allotment Details

The company allotted 2,82,000 equity shares with a face value of ₹5 each to five public category allottees. The aggregate amount raised from this tranche is ₹7,05,00,000.

Consequent to this allotment, the paid-up equity share capital increased to ₹8,01,61,825, comprising 1,60,32,365 equity shares.

Warrant Allotment Details

The company also allotted 9,47,990 fully convertible warrants at ₹250 each, raising an aggregate of ₹23,69,97,500. Growel Remedies Limited, classified under the promoter category, received the largest allocation.

On a fully diluted basis, the paid-up equity share capital will stand at ₹8,49,01,775, comprising 1,69,80,355 equity shares.

What the Numbers Show

The warrant component constitutes approximately 77% of the total capital raised in this transaction. This structure suggests a strategic preference for deferred equity conversion, allowing the company to raise immediate cash while diluting existing shareholders only upon future exercise of the warrants.